Clinical Trial Update: A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating AQW051 once-daily dosing on cognition in stable schizophrenia patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AQW051

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED